ID   T921
AC   CVCL_T057
DR   Wikidata; Q54971633
RX   Patent=CN102344910A;
RX   PubMed=23813186;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201180.
CC   Population: Chinese.
CC   Doubling time: 48-72 hours (PubMed=23813186).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 11
//
RX   Patent=CN102344910A;
RA   Ren S.-C., Sun Y.-H., Xu W.-D., Xu C.-L.;
RT   "Human bladder cancer cell line.";
RL   Patent number CN102344910A, 08-Feb-2012.
//
RX   PubMed=23813186; DOI=10.1007/s11626-013-9651-z;
RA   Xu C.-L., Xu W.-D., Ren S.-C., Wu C.-Y., Wang F.-B., Lu J., Sun Y.,
RA   Shen J., Wei M., Zhang Z.-S., Gao X., Sun Y.-H.;
RT   "Establishment of a Chinese bladder cancer cell line (T921) with high
RT   metastatic activity.";
RL   In Vitro Cell. Dev. Biol. Anim. 49:668-678(2013).
//